Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Telix Pharmaceuticals Limited TLPPF OTC

Other OTC • Healthcare • Biotechnology • AU • USD

SharesGrow Score
53/100
2/5 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Telix Pharmaceuticals Limited (TLPPF) is a Biotechnology company in the Healthcare sector, currently trading at $10.50. It has a SharesGrow Score of 50/100, indicating a mixed investment profile with 2 out of 7 criteria passed.

Financials: revenue is $1.2B, +109.6%/yr average growth. Net income is $11M (loss), growing at +280.3%/yr. Net profit margin is -0.9% (negative). Gross margin is 53.1% (+34.8 pp trend).

Balance sheet: total debt is $785M against $623M equity (Debt-to-Equity (D/E) ratio 1.26, moderate). Current ratio is 1.43 (adequate). Debt-to-assets is 44.3%. Total assets: $1.8B.

SharesGrow 7-Criteria breakdown: Value ?/100 (Fail), Growth 100/100 (Pass), Past 50/100 (Partial), Health 33/100 (Fail), Moat 74/100 (Pass), Future ?/100 (Fail), Income 10/100 (Fail).

TLPPF SharesGrow Score Overview

53/100
SharesGrow Score
Mixed signals — some strengths
View full scorecard →
VALUE 0/100
Valuation — P/E, PEG, Forward PEG
GROWTH 100/100
Financials — average growth
PAST 50/100
strong — trend
HEALTH 33/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 74/100
Gross margin is + market cap
FUTURE 0/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — TLPPF

—
VALUE N/A
N/A
No analyst coverage available for this stock.
✓
GROWTH Pass
100/100
TLPPF: +109.6%/yr revenue is, +280.3%/yr Net income is average growth. > 5%/yr — strong. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
~
PAST Partial
50/100
TLPPF: 2 / 4 years profitable. weak. Score = 2 / 4 × 100. ≥ 80 = Pass.
View details →
✗
HEALTH Fail
33/100
Balance sheet TLPPF: Debt-to-Equity (D/E) ratio 1.26 (moderate), Current ratio is 1.43 (adequate). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
✓
MOAT Pass
74/100
TLPPF: Gross margin is 53.1% (+34.8 pp trend), $4B market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 74/100. ≥ 70 = Pass.
View details →
—
FUTURE N/A
N/A
No analyst coverage available for this stock.
✗
INCOME Fail
10/100
TLPPF: Net profit margin is -0.9%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range5.91-19.99
Volume2.96K
Avg Volume (30D)3.45K
Market Cap$3.56B
Beta (1Y)0.61
Share Statistics
EPS (TTM)-0.03
Shares Outstanding$337.88M
IPO Date2019-07-25
Employees415
CEOChristian Behrenbruch
Financial Highlights & Ratios
Revenue (TTM)$1.25B
Gross Profit$661.81M
EBITDA$82.52M
Net Income$-11.05M
Operating Income$27.54M
Total Cash$212.66M
Total Debt$784.94M
Net Debt$572.28M
Total Assets$1.77B
Price / Earnings (P/E)-321.1
Price / Sales (P/S)2.85
Analyst Forecast
Company Info
CountryAU
ExchangeOther OTC
CurrencyUSD
ISINAU000000TLX2

Price Chart

Track all markets on TradingView
TLPPF
Telix Pharmaceuticals Limited ↗  ·  Other OTC
Healthcare • Biotechnology
5.91 52WK RANGE 19.99

People Also View

IVBXF
IVBXF
Innovent Biologics, Inc.
$10.55
+2.48%
 PCVX
PCVX
Vaxcyte, Inc.
$60.45
-3.68%
 ACLX
ACLX
Arcellx, Inc.
$115.00
+0.10%
 GNNSF
GNNSF
Genscript Biotech Corporation
$1.42
+0.00%
 DICE
DICE
DICE Therapeutics, Inc.
$47.55
+0.06%
 ROIVW
ROIVW
Roivant Sciences Ltd.
$2.75
+4.56%
 IMCR
IMCR
Immunocore Holdings plc
$31.64
-0.16%
 VTYX
VTYX
Ventyx Biosciences, Inc.
$14.00
+0.00%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message